145 related articles for article (PubMed ID: 3526454)
1. Pubertal growth: physiology and pathophysiology.
Cutler GB; Cassorla FG; Ross JL; Pescovitz OH; Barnes KM; Comite F; Feuillan PP; Laue L; Foster CM; Kenigsberg D
Recent Prog Horm Res; 1986; 42():443-70. PubMed ID: 3526454
[No Abstract] [Full Text] [Related]
2. Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome.
Foster CM; Comite F; Pescovitz OH; Ross JL; Loriaux DL; Cutler GB
J Clin Endocrinol Metab; 1984 Oct; 59(4):801-5. PubMed ID: 6434582
[TBL] [Abstract][Full Text] [Related]
3. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
Feuillan PP; Foster CM; Pescovitz OH; Hench KD; Shawker T; Dwyer A; Malley JD; Barnes K; Loriaux DL; Cutler GB
N Engl J Med; 1986 Oct; 315(18):1115-9. PubMed ID: 3093862
[TBL] [Abstract][Full Text] [Related]
4. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
Feuillan PP; Jones J; Cutler GB
J Clin Endocrinol Metab; 1993 Sep; 77(3):647-51. PubMed ID: 8370686
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome.
Feuillan PP; Jones J; Oerter KE; Manasco PK; Cutler GB
J Clin Endocrinol Metab; 1991 Dec; 73(6):1370-3. PubMed ID: 1955519
[TBL] [Abstract][Full Text] [Related]
6. Cyclical ovarian function resistant to treatment with an analogue of luteinizing hormone releasing hormone in McCune-Albright syndrome.
Comite F; Shawker TH; Pescovitz OH; Loriaux DL; Cutler GB
N Engl J Med; 1984 Oct; 311(16):1032-6. PubMed ID: 6434946
[No Abstract] [Full Text] [Related]
7. Testolactone treatment of precocious puberty in McCune-Albright syndrome.
Foster CM; Pescovitz OH; Comite F; Feuillan P; Shawker T; Loriaux DL; Cutler GB
Acta Endocrinol (Copenh); 1985 Jun; 109(2):254-7. PubMed ID: 3925675
[TBL] [Abstract][Full Text] [Related]
8. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
[TBL] [Abstract][Full Text] [Related]
9. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin.
Laue L; Jones J; Barnes KM; Cutler GB
J Clin Endocrinol Metab; 1993 Jan; 76(1):151-5. PubMed ID: 8421081
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome: patient report and literature review.
Sawathiparnich P; Osuwanaratana P; Santiprabhob J; Likitmaskul S
J Pediatr Endocrinol Metab; 2006 Jan; 19(1):81-6. PubMed ID: 16509532
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of post-menarche idiopathic central precocious puberty in girls with combined gonadotropin-releasing hormone analog and growth hormone].
Li Y; Liang L; Sun LY; Dong GP
Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):627-8. PubMed ID: 16191282
[No Abstract] [Full Text] [Related]
12. Familial male precocious puberty.
Laue L; Cutler GB
Curr Ther Endocrinol Metab; 1994; 5():296-9. PubMed ID: 7704737
[No Abstract] [Full Text] [Related]
13. Use of aromatase inhibitors in precocious puberty.
Feuillan P; Merke D; Leschek EW; Cutler GB
Endocr Relat Cancer; 1999 Jun; 6(2):303-6. PubMed ID: 10731123
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin independent precocious puberty.
Low LC; Wang Q
J Pediatr Endocrinol Metab; 1998; 11(4):497-507. PubMed ID: 9777570
[TBL] [Abstract][Full Text] [Related]
15. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty.
Mansfield MJ; Rudlin CR; Crigler JF; Karol KA; Crawford JD; Boepple PA; Crowley WF
J Clin Endocrinol Metab; 1988 Jan; 66(1):3-9. PubMed ID: 2961786
[TBL] [Abstract][Full Text] [Related]
16. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.
Pescovitz OH; Comite F; Hench K; Barnes K; McNemar A; Foster C; Kenigsberg D; Loriaux DL; Cutler GB
J Pediatr; 1986 Jan; 108(1):47-54. PubMed ID: 3080571
[TBL] [Abstract][Full Text] [Related]
17. Pubertal disorders and bone maturation.
Lazar L; Phillip M
Endocrinol Metab Clin North Am; 2012 Dec; 41(4):805-25. PubMed ID: 23099272
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement.
Veldhuis JD; Metzger DL; Martha PM; Mauras N; Kerrigan JR; Keenan B; Rogol AD; Pincus SM
J Clin Endocrinol Metab; 1997 Oct; 82(10):3414-20. PubMed ID: 9329378
[TBL] [Abstract][Full Text] [Related]
19. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.
Cara JF; Kreiter ML; Rosenfield RL
J Pediatr; 1992 May; 120(5):709-15. PubMed ID: 1533661
[TBL] [Abstract][Full Text] [Related]
20. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty.
Kamp GA; Manasco PK; Barnes KM; Jones J; Rose SR; Hill SC; Cutler GB
J Clin Endocrinol Metab; 1991 Feb; 72(2):301-7. PubMed ID: 1991801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
